Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

Precipio Diagnostics reported a record $7.0 million in second-quarter revenue, marking a 22.8% increase from the previous year. The company returned to positive adjusted EBITDA and generated $700,000 in operating cash flow. Management highlighted the growth of the Rapid AML Panel and a widening commercial pipeline as key drivers of the strong performance.

The pathogen business revenue rose to $6.1 million, while product revenue increased to $900,000, accounting for 12.9% of total sales. This quarter was a milestone as Precipio became the first to exceed $7 million in revenue, with a market capitalization of $42.84 million and a 62.6% total return over the past year.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.